Dr. Talal Hilal, a lymphoma expert from UT Southwestern in Dallas, Texas, joins HealthTree to discuss genomics, the study of a person’s genes, and how this information can benefit patients with both indolent (slow-growing) and aggressive lymphomas. Watch the video or read the summary below.
Dr. Hilal and his team at UT Southwestern are attempting to refine the characterization of higher-risk follicular lymphoma. Follicular lymphoma typically progresses slowly and can often be effectively managed, allowing individuals to lead fulfilling lives. However, certain subtypes are far more aggressive, posing challenges in predicting disease prognosis.
To address this uncertainty, they are utilizing genomic techniques, such as gene expression profiling, alongside the analysis of clinical variables. By examining these factors, they aim to define subsets of follicular lymphoma patients who are at higher risk of disease progression or poorer outcomes.
The ultimate goal of Dr. Hilal’s research is to identify individuals who stand to gain greater benefit from early intervention or closer follow-up. This approach will tailor treatment strategies to the specific needs of higher-risk follicular lymphoma patients, improving therapeutic outcomes while minimizing unnecessary interventions for those with more slow-growing forms of the disease.
Want to help accelerate a cure for follicular lymphoma? Get involved in research by joining HealthTree Cure Hub to support real-world data research that aims to improve the lives of patients!
